RESEARCH

Open Access



Metabolic engineering of *Saccharomyces Cerevisiae* to produce 1-hexadecanol from xylose

Weihua Guo^{1†}, Jiayuan Sheng^{1†}, Huimin Zhao^{2*} and Xueyang Feng^{1*}

Abstract

Background: An advantageous but challenging approach to overcome the limited supply of petroleum and relieve the greenhouse effect is to produce bulk chemicals from renewable materials. Fatty alcohols, with a billion-dollar global market, are important raw chemicals for detergents, emulsifiers, lubricants, and cosmetics production. Microbial production of fatty alcohols has been successfully achieved in several industrial microorganisms. However, most of the achievements were using glucose, an edible sugar, as the carbon source. To produce fatty alcohols in a renewable manner, non-edible sugars such as xylose will be a more appropriate feedstock.

Results: In this study, we aim to engineer a *Saccharomyces cerevisiae* strain that can efficiently convert xylose to fatty alcohols. To this end, we first introduced the fungal xylose utilization pathway consisting of xylose reductase (XR), xylitol dehydrogenase (XDH), and xylulose kinase (XKS) into a fatty alcohol-producing *S. cerevisiae* strain (XF3) that was developed in our previous studies to achieve 1-hexadecanol production from xylose at 0.4 g/L. We next applied promoter engineering on the xylose utilization pathway to optimize the expression levels of XR, XDH, and XKS, and increased the 1-hexadecanol titer by 171 %. To further improve the xylose-based fatty alcohol production, two optimized *S. cerevisiae* strains from promoter engineering were evolved with the xylose as the sole carbon source. We found that the cell growth rate was improved at the expense of decreased fatty alcohol production, which indicated 1-hexadecanol was mainly produced as a non-growth associated product. Finally, through fed-batch fermentation, we successfully achieved 1-hexadecanol production at over 1.2 g/L using xylose as the sole carbon source, which represents the highest titer of xylose-based 1-hexadecanol reported in microbes to date.

Conclusions: A fatty alcohol-producing *S. cerevisiae* strain was engineered in this study to produce 1-hexadecanol from xylose. Although the xylose pathway we developed in this study could be further improved, this proof-of-concept study, for the first time to our best knowledge, demonstrated that the xylose-based fatty alcohol could be produced in *S. cerevisiae* with potential applications in developing consolidated bioprocessing for producing other fatty acid-derived chemicals.

Keywords: Yeast, Promoter engineering, Evolutionary engineering, Fatty alcohols

Background

Producing bulk chemicals from renewable resources could reduce strong dependence on petroleum and the damage to the environment [1, 2]. As important chemicals with a billion-dollar market globally [3, 4], fatty

[†]Weihua Guo and Jiayuan Sheng contributed equally to this work

¹ Department of Biological Systems Engineering, Virginia Polytechnic

Institute and State University, Blacksburg, VA 24061, USA

² Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA



Recently, with the development of metabolic engineering and synthetic biology, microbial production of fatty alcohols from renewable feedstock has been achieved successfully in both *Escherichia coli* [4, 9] and



© 2016 Guo et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

^{*}Correspondence: zhao5@illinois.edu; xueyang@vt.edu

Full list of author information is available at the end of the article

Saccharomyces cerevisiae [3, 10]. So far, the highest titer of fatty alcohols produced was 1.95 [11] and 1.1 g/L [10] by E. coli and S. cerevisiae respectively. A significantly higher titer of fatty alcohols was recently reported to be produced by *R. toloroides* [12]. In *E. coli*, fatty alcohols have been produced by introducing heterologous enzymes such as fatty acyl-CoA reductase (FAR) [13], carboxylic acid reductase (CAR) [14] together with aldehyde reductases (AR), or acyl-CoA reductase (ACR) together with AR [4, 15]. Compared to that in E. coli, the synthetic route (i.e., steps of enzymatic reactions) of fatty acyl-CoA is shorter in yeast, which allows more efficient conversion of carbohydrate substrates to fatty acids and fatty acid-derived biofuels [9]. Also, as a well characterized robust industrial host, yeast can grow under low pH and various harsh fermentation conditions [16]. Therefore, there has been an increasing interest on developing yeast, such as S. cerevisiae, as a cell factory for fatty acidderived biofuel production. In S. cerevisiae, a mouse FAR has been expressed to produce 1-hexadecanol [10]. Through over-expression of acetyl-CoA carboxylase (ACC) and fatty-acyl-CoA synthases (FAS), the engineered S. cerevisiae strain produced 98.0 mg/L total fatty alcohol from 20 g/L glucose in batch culture in minimal medium [3]. Recently, by manipulating the structural genes in yeast lipid metabolism, tuning the regulation of phospholipid synthesis, and increasing the supply of key precursors, 1-hexadecanol was produced at 1.1 g/L using glucose as the carbon source in a fed-batch fermentation [10].

One of the limitations for current research on metabolic engineering to produce fatty acid-derived chemicals is that almost all of the achievements were based on glucose as the carbon source. To produce biofuels and biochemicals in a renewable manner, non-edible sugars such as xylose will be a more appropriate feedstock. Recently, engineering S. cerevisiae to utilize xylose is of great interest to the biofuel industry and could solve the major bottleneck in complete and efficient conversion of cellulosic sugars present in solubilized cell wall of plants into biofuels [17]. The sugar D-xylose, derived from hydrolysis of hemicellulose, is the second most abundant sugar in the plant cell wall consisting of up to 35 % of the total carbohydrate from lignocellulose biomass [18]. However, since the yeast S. cerevisiae cannot metabolize xylose, heterologous xylose utilization pathways need to be introduced into S. cerevisiae to achieve this objective. Two different pathways for the catabolism of D-xylose have been established in S. cerevisiae: the fungal xylose pathway consisting of xylose reductase (XR), xylitol dehydrogenase (XDH), and xylulose kinase (XKS) [17, 19–21], and the xylose pathway using the enzyme, xylose isomerase, to convert D-xylose directly into D-xylulose [22, 23],

followed by the phosphorylation of D-xylulose to D-xylulose-5-phosphate. Recently, xylose isomerase has been successfully used in an industrial yeast strain [24].

In this study, we aim to engineer a S. cerevisiae strain that can efficiently convert xylose to fatty alcohols, by expressing a heterologous fungal xylose pathway into a 1-hexadecanol-producing S. cerevisiae strain that has been previously developed. We chose a S. cerevisiae strain, namely XF3, as our host since it has been engineered to produce 1-hexadecanol at over 1 g/L from glucose, and introduced XR, XDH, and XKS into XF3 to utilize xylose as the sole carbon source. Then, by applying combinatorial promoter engineering and evolutionary engineering, the production of 1-hexadecanol was enhanced by 171 %. Finally, over 1.2 g/L 1-hexadecanol was produced in a fed-batch fermentation using xylose as the sole carbon source, which is at the similar level when using the glucose as the carbon source [10]. To our best knowledge, it is the first time that yeast was engineered to use a pentose sugar for producing fatty acid-derived biofuels.

Methods

Yeast strains, media, and transformation

The yeast strains used in this study were derived from BY4742 (Table 1). Yeast and bacterial strains were stored in 25 % glycerol at -80 °C. E. coli DH5α strain was used to maintain and amplify plasmids, and recombinant strains were cultured at 37 °C in Luria-Bertani (LB) broth. Ampicillin at 100 µg/mL was added to the medium when required. Yeast BY4742 strains were cultivated in YPAD medium. Yeast cells were transformed with plasmids listed in Table 1 using the LiAc/PEG method as described previously [25]. To select the yeast transformants, a synthetic complete (SC) medium was used, which contains 0.17 % yeast nitrogen base, 0.5 % ammonium sulfate, and the appropriate amino acids dropout mix (MP Biomedicals, Solon, OH). A single colony was picked and cultivated in 5 mL SC medium containing 20 g/L glucose. The cells were cultivated at 30 °C in disposable culture tubes shaken at 250 rpm for 2 days.

Plasmid construction

A yeast homologous recombination-based method, DNA assembler [26], was used to construct the recombinant plasmids. Briefly, DNA fragments sharing homologous regions to adjacent DNA fragments were co-transformed into *S. cerevisiae* along with the linearized backbone to assemble several elements in a single step [27]. Oligonucleotides used in this study were listed in Additional file 1: Table S1 and the recombinant plasmids construct de library for promoter engineering, the csXR was amplified

Name

Table 1 Plasmids and strains used in this study

Description

pHaRA_ACCI pR4925TRF1p346AL2TPITOR(1p4CC1+AUT? [39] pVKAL pR4925TRF1p346AL2TPITOR[1p4CC1+BV2p0]-ppXK5ADP2 This study pVFX02 pR4146PDC1p0]-cSRAADPITETF1p1]-cXDH-CVC1+RV2p0]-ppXK5ADP2 This study pVFX03 pR4146PDC1p0]-cSRAADPITETF1p1]-cXDH-CVC1+RV2p0]-ppXK5ADP2 This study pVFX04 pR4146PDC1p0]-cSRAADPITETF1p1W-cXDH-CVC1+RV2p0PK5ADP2 This study pVFX05 pR4146PDC1p0]-cSRAADPITETF1p1W-cXDH-CVC1+RV2p0PK5ADP2 This study pVFX06 pR4146PDC1p0]-cSRAADPITETF1p1W-cXDH-CVC1+RV2p0PK5ADP2 This study pVFX07 pR4146PDC1p0]-cSRAADPITETF1p1W-cXDH-CVC1+RV2p0PK5ADP2 This study pVFX08 pR4146PDC1p0]-cSRAADPITETF1p1W-cXDH-CVC1+RV2p0W-ppXK5ADP2 This study pVFX10 pR4146PDC1p0J-cSRAADPITETF1p1W-cXDH-CVC1+RV2p0W-ppXK5ADP2 This study pVFX11 pR4146PDC1p0M-cSRAADPITETF1p1W-cXDH-CVC1+RV2p0W-ppXK5ADP12 This study pVFX11 pR4146PDC1p0M-cSRAADPITETF1p1W-cXDH-CVC1+RV2p0W-ppXK5ADP12 This study pVFX11 pR4146PDC1p0M-cSRAADPITETF1p1W-cXDH-CVC1+RV2p0W-ppXK5ADP12 This study pVFX11 pR4146PDC1p0M-cSRAADPITETF1p1W-cXDH-CVC1+RV2p0W-ppXK5ADP12 This study pVFX11 pR4	Plasmids used in this study				
pVMCL p842a-TR1p pVMCL p18 p87300 p8416-PDC1pU-cx8A-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87302 p8416-PDC1pU-cx8A-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87303 p8416-PDC1pU-cx8A-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87304 p8416-PDC1pU-cx8A-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87305 p8416-PDC1pU-cx8A-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87306 p8416-PDC1pU-cx8A-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87307 p8416-PDC1pU-cx8A-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87308 p8416-PDC1pU-cx8A-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87309 p8416-PDC1pU-cxRA-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87310 p8416-PDC1pU-cxRA-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87311 p8416-PDC1pU-cxRA-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87311 p8416-PDC1pU-cxRA-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p87311 p8416-PDC1pU-cxRA-ADH1-TEF1pU-cxDH-CV1E-NO2pM/spXKS-ADH2 This study p873116 <td< td=""><td>pTaFAR_ACC1</td><td>pRS425-TEF1p-TaFAR-TEF1t-PGK1p-ACC1-HXT7t</td><td></td><td>[36]</td><td></td></td<>	pTaFAR_ACC1	pRS425-TEF1p-TaFAR-TEF1t-PGK1p-ACC1-HXT7t		[36]	
pR5101 pR516 POC [p1]-csR4 ADH11ETE [p1]-ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5103 pR516 POC [p1]-csR4 ADH11ETE [p1]-ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5104 pR516 POC [p1]-csR4 ADH11ETE [p1]/ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5105 pR5116 POC [p1]-csR4 ADH11ETE [p1]/ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5105 pR5116 POC [p1]-csR4 ADH11ETE [p1]/ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5105 pR5116 POC [p1]-csR4 ADH11ETE [p1]/ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5106 pR5116 POC [p1]-csR4 ADH11ETE [p1]/ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5110 pR5116 POC [p1]/csR4 ADH11ETE [p1]/ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5111 pR5116 POC [p1]/csR4 ADH11ETE [p1]/ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5111 pR5116 POC [p1]/csR4 ADH11ETE [p1]/ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5111 pR5116 POC [p1]/csR4 ADH11ETE [p1]/ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5111 pR5116 POC [p1]/csR4 ADH11ETE [p1]/ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5111 pR5116 POC [p1]/csR4 ADH11ETE [p1]/ctXDH-CYC1E-NO220L1-pXK5 ADH21 This study pR5111	pYIACL	pRS423-TPI1p-YIACL1-TPI1t-TEF1p-YIACL2-TEF1t		[39]	
pXF3002 pK416 PDC [pLi>=CXRA.PDH ITEF[pLi]==CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3003 pK516 PDC [pLi>=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3004 pK516 PDC [pLi)=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3005 pK516 PDC [pLi)=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3006 pK516 PDC [pLi)=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3007 pK516 PDC [pLi)=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3008 pK516 PDC [pVI]=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3010 pK5416 PDC [pVI]=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3111 pK5416 PDC [pVI]=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3113 pK5416 PDC [pVI]=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3113 pK5416 PDC [pVI]=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3113 pK5416 PDC [pVI]=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study pXF3114 pK5416 PDC [pVI]=CXRA.PDH ITEF[pVI]=CXDH -CYC1 t=R02p(M)-pXK5.ADH2t This study	pXF3X01	pRS416-PDC1p(L)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2	p(L)-ppXKS-ADH2t	This study	
pK3103 pK311 6 PDC [pL):cx88.ADH1:TEF1 [pL):cx80.ADH2; This study pXF3X04 pK316 6 PDC [pL):cx88.ADH1:TEF1 [pL):cx80.ADH2; This study pXF3X05 pK316 6 PDC [pL):cx88.ADH1:TEF1 [pL):cx80.ACH2; This study pXF3X05 pK316 6 PDC [pL):cx88.ADH1:TEF1 [pL:0+CX01-CVC1:EN02p(I):ppX5AOH2; This study pXF3X07 pK341 6 PDC [pL):cx88.ADH1:TEF1 [pL:0+CX01-CVC1:EN02p(I):ppX5AOH2; This study pXF3X09 pK341 6 PDC [pL):cx88.ADH1:TEF1 [pL:0+CX01-EN02p(I):ppX5AOH2; This study pXF3X09 pK341 6 PDC [pL):cx88.ADH1:TEF1 [pL:0+CX01-EVC1:EN02p(I):ppX5AOH2; This study pXF3X10 pK316 6 PDC [pL/0:cx88.ADH1:TEF1 [pL:0+CX01-EVC1:EN02p(I):ppX5AOH2; This study pXF3X13 pK316 6 PDC [pL/0:cx88.ADH1:TEF1 [pL:0+CX01-EVC1:EN02p(I):ppX5AOH2; This study pXF3X14 pK316 6 PDC [pL/0:cx88.ADH1:TEF1 [pL:0+CX01-EVC1:EN02p(I):ppX5AOH2; This study pXF3X17 pK316 6 PDC [pL/0:cx88.ADH1:TEF1 [pL]:0+CX01-EVC1:EN02p(I):ppX5AOH2; This study pXF3X17 pK316 6 PDC [pL/0:cx88.ADH1:TEF1 [pL:0+CX01-EVC1:EN02p(I):ppX5AOH2; This study pXF3X17 pK316 6 PDC [pL/0:cx88.ADH1:TEF1 [pL:0+CX01-EVC1:EN02p(I):ppX5AOH2; This study pXF3X17 pK316 6 PDC [pL/0:cx88.ADH	pXF3X02	pRS416-PDC1p(L)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2	p(M)-ppXKS-ADH2t	This study	
pX8304 pK8416-PDC1pLL-sXR+ADH1*TEF1pM-cXDH-CYC1E-R02pU-ppK8-ADH2; This study pX8306 pK8416-PDC1pLL-sXR+ADH1*TEF1pM-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX8306 pK8416-PDC1pLL-sXR+ADH1*TEF1pM-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX8307 pK8416-PDC1pLL-sXR+ADH1*TEF1pM1-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX8308 pK8416-PDC1pLL-sXR+ADH1*TEF1p101-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX7310 pK8416-PDC1pM0-sXR-ADH1*TEF1p101-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX7311 pK8416-PDC1pM0-sXR-ADH1*TEF1p101-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX7311 pK6416-PDC1pM0-sXR-ADH1*TEF1p101-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX7311 pK6416-PDC1pM0-cXR-ADH1*TEF1p101-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX7311 pK6416-PDC1pM0-cXR-ADH1*TEF1p101-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX73116 pK6416-PDC1pM0-cXR-ADH1*TEF1p101-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX73116 pK6416-PDC1pM0-cXR-ADH1*TEF1p101-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX73116 pK6416-PDC1pM0-cXR-ADH1*TEF1p101-cXDH-CYC1E-R02pU/ppK8-ADH2; This study pX73117 pK6416-PDC1pM0-cXR-ADH1*TEF1p101-cXDH-CYC1E-R02pU/ppK8-ADH2;	pXF3X03	pRS416-PDC1p(L)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2	p(H)-ppXKS-ADH2t	This study	
pXF3X05 pF8416-PDC1pUt-cXRA.DH1+TEF1p(M-cXD1+CVC1+EN02p(M)-ppXKS-ADH2t This study pXF3X06 pF8416-PDC1pUt-cXRA.DH1+TEF1p(M-cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X07 pF8416-PDC1pUt-cXRA.ADH1+TEF1p(M-cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X08 pF8416-PDC1pUt-cXRA.ADH1+TEF1p(D+cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X01 pF8416-PDC1p(M-cXRA.ADH1+TEF1p(D+cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X11 pF8416-PDC1p(M-cXRA.ADH1+TEF1p(D+cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X13 pF8416-PDC1p(M-cXRA.ADH1+TEF1p(D+cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X13 pF8416-PDC1p(M-cXRA.ADH1+TEF1p(M-cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X16 pF8416-PDC1p(M-cXRA.ADH1+TEF1p(M-cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X17 pF8416-PDC1p(M-cXRA.ADH1+TEF1p(M-cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X17 pF8416-PDC1p(M-cXRA.ADH1+TEF1p(M-cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X17 pF8416-PDC1p(M-cXRA.ADH1+TEF1p(M-cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X19 pF8416-PDC1p(M-cXRA.ADH1+TEF1p(M-cXD1+CVC1+EN02p(L)-ppXKS-ADH2t This study pXF3X20 pF8416-PDC1	pXF3X04	pRS416-PDC1p(L)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO	2p(L)-ppXKS-ADH2t	This study	
pxF3306 p6F316-PDC1p(1)-cxR-ADH1TEF1p(M)-cXDH-CYC1-ENO2p(H)-pxXS-ADH2; This study pxF3306 p6F316-PDC1p(1)-cxR-ADH1TEF1p(H)-cXDH-CYC1-ENO2p(H)-pxXS-ADH2; This study pxF3307 p6F316-PDC1p(L)-cxR-ADH1TEF1p(H)-cXDH-CYC1-ENO2p(H)-pxXS-ADH2; This study pxF3308 p6F316-PDC1p(M)-cxR-ADH1TEF1p(L)-cXDH-CYC1-ENO2p(H)-pxXS-ADH2; This study pxF3310 p6F316-PDC1p(M)-cxR-ADH1TEF1p(L)-cXDH-CYC1-ENO2p(H)-pxXS-ADH2; This study pxF3311 p6F316-PDC1p(M)-cxR-ADH1TEF1p(M)-cXDH-CYC1-ENO2p(H)-pxXS-ADH2; This study pxF3313 p6F316-PDC1p(M)-cxR-ADH1TEF1p(M)-cXDH-CYC1-ENO2p(M)-pxXS-ADH2; This study pxF3313 p6F316-PDC1p(M)-cxR-ADH1TEF1p(M)-cXDH-CYC1-ENO2p(M)-pxXS-ADH2; This study pxF3317 p6F316-PDC1p(M)-cxR-ADH1TEF1p(M)-cXDH-CYC1-ENO2p(M)-pxXS-ADH2; This study pxF3317 p6F316-PDC1p(M)-cxR-ADH1TEF1p(M)-cXDH-CYC1-ENO2p(M)-pxXS-ADH2; This study pxF3317 p6F316-PDC1p(M)-cxR-ADH1TEF1p(M)-cXDH-CYC1-ENO2p(M)-pxXS-ADH2; This study pxF3317 p6F316-PDC1p(M)-cxR-ADH1TEF1p(M)-cXDH-CYC1-ENO2p(M)-pxXS-ADH2; This study pxF3320 p6F316-PDC1p(M)-cxR-ADH1TEF1p(M)-cXDH-CYC1-ENO2p(M)-pxXS-ADH2; This study pxF3321 p6F316-PDC1p(M)-cxR-AD	pXF3X05	pRS416-PDC1p(L)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO	2p(M)-ppXKS-ADH2t	This study	
pxF3x07 pF6416-PDC1pU1-cxR4.ADH1:TEF1p01-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pxF3x08 pR5416-PDC1pU1-cxR4.ADH1:TEF1p01-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pxF3x09 pR5416-PDC1pU1-cxR4.ADH1:TEF1p01-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pxF3x10 pR5416-PDC1pUM-csR4.ADH1:TEF1p01-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pXF3x11 pR5416-PDC1pUM-csR4.ADH1:TEF1p01-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pXF3x13 pR5416-PDC1pUM-csR4.ADH1:TEF1p010-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pXF3x13 pR5416-PDC1pUM-csR4.ADH1:TEF1p010-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pXF3x16 pR5416-PDC1pUM-csR4.ADH1:TEF1p010-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pXF3x17 pR5416-PDC1pUM-csR4.ADH1:TEF1p010-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pXF3x19 pR5416-PDC1pUM-csR4.ADH1:TEF1p010-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pXF3x19 pR5416-PDC1pUM-csR4.ADH1:TEF1p010-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pXF3x21 pR5416-PDC1pUH-csR4.ADH1:TEF1p010-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study pXF3x21 pR5416-PDC1pUH-csR4.ADH1:TEF1p010-cxX0H-CVC1t-END2p0U1-ppXK5-ADH2t This study	pXF3X06	pRS416-PDC1p(L)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO	2p(H)-ppXKS-ADH2t	This study	
pXF3X08 pR5416-PDC1pU-cx8A-ADH1*TEF1pUH-cxXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X09 pR5416-PDC1pUh-cx8A-ADH1*TEF1pL-CXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X11 pR5416-PDC1pUh-cx8A-ADH1*TEF1pL-CXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X12 pR5416-PDC1pUh-cx8A-ADH1*TEF1pUh-cXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X13 pR5416-PDC1pUh-cx8A-ADH1*TEF1pUh-cXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X14 pR5416-PDC1pUh-cx8A-ADH1*TEF1pUh-cXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X15 pR5416-PDC1pUh-cx8A-ADH1*TEF1pUh-cXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X16 pR5416-PDC1pUh-cx8A-ADH1*TEF1pUh-cXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X16 pR5416-PDC1pUh-cx8A-ADH1*TEF1pUh-cXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X16 pR5416-PDC1pUh-cx8A-ADH1*TEF1pUh-cXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X20 pR5416-PDC1pUh-cx8A-ADH1*TEF1pUh-cXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X21 pR5416-PDC1pUh-cx8A-ADH1*TEF1pUh-cXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X20 pR5416-PDC1pUh-cx8A-ADH1*TEF1pUh-cXXDH-CYC1t-ENO2pUh-pXKS-ADH2; This study pXF3X22 pR5416-PDC1p	pXF3X07	pRS416-PDC1p(L)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2	2p(L)-ppXKS-ADH2t	This study	
pXF3X09 pR5416-PDC1ptU-cxXR-ADH1+TEF1ptU-cxXDH-CYC1E-R02ptU-pxXK-ADH2t This study pXF3X10 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pLU-cxXDH-CYC1E-R02ptU-pxXK-ADH2t This study pXF3X11 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pLU-cxXDH-CYC1E-R02ptU-pxXK-ADH2t This study pXF3X11 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pU0-cxXDH-CYC1E-R02ptU0-pxXK-ADH2t This study pXF3X14 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pU0-cxXDH-CYC1E-R02ptU0-pxXK-ADH2t This study pXF3X15 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pU0-cxXDH-CYC1E-R02ptW0-pxXK-ADH2t This study pXF3X16 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pU0-cxXDH-CYC1E-R02ptW0-pxXK-ADH2t This study pXF3X17 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pU0-cxXDH-CYC1E-R02ptW0-pxXK-ADH2t This study pXF3X18 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pU0-cxXDH-CYC1E-R02ptW0-pxXK-ADH2t This study pXF3X19 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pU0-cxXDH-CYC1E-R02ptW0-pxXK-ADH2t This study pXF3X20 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pU0-cxXDH-CYC1E-R02ptW0-pxXK-ADH2t This study pXF3X21 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pU0-cxXDH-CYC1E-R02ptW0-pxXK-ADH2t This study pXF3X20 pR5416-PDC1ptW0-cxXR-ADH1+TEF1pU0-cxXDH-CYC1E-R02ptW0-pxXK-ADH2t This study pXF3X20	pXF3X08	pRS416-PDC1p(L)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO	2p(M)-ppXKS-ADH2t	This study	
pXF3X10 pRF316-PDC1pI/M)-csXR-ADH11-TEF1pI/DctXDH-CVC1E-EN02pI/L)-ppXK-ADH2t This study pXF3X12 pRF416-PDC1pI/M)-csXR-ADH11-TEF1pI/DctXDH-CVC1E-EN02pI/L)-ppXK-ADH2t This study pXF3X12 pR5116-PDC1pI/M)-csXR-ADH11-TEF1pI/DctXDH-CVC1E-EN02pI/L)-ppXKS-ADH2t This study pXF3X13 pR5116-PDC1pI/M)-csXR-ADH11-TEF1pI/M-ctXDH-CVC1E-EN02pI/L)-ppXKS-ADH2t This study pXF3X16 pR5116-PDC1pI/M)-csXR-ADH11-TEF1pI/M-ctXDH-CVC1E-EN02pI/L)-ppXKS-ADH2t This study pXF3X16 pR5116-PDC1pI/M)-csXR-ADH11-TEF1pI/M-ctXDH-CVC1E-EN02pI/L)-ppXKS-ADH2t This study pXF3X17 pR5116-PDC1pI/M)-csXR-ADH11-TEF1pI/M-ctXDH-CVC1E-EN02pI/L)-ppXKS-ADH2t This study pXF3X19 pR5116-PDC1pI/M)-csXR-ADH11-TEF1pI/M-ctXDH-CVC1E-EN02pI/L)-ppXKS-ADH2t This study pXF3X20 pR5116-PDC1pI/M)-csXR-ADH11-TEF1pI/M-ctXDH-CVC1E-EN02pI/L)-ppXKS-ADH2t This study pXF3X21 pR5116-PDC1pI/M-csXR-ADH11-TEF1pI/M-ctXDH-CVC1E-EN02pI/L)-ppXKS-ADH2t This study pXF3X23 pR5116-PDC1pI/M-csXR-ADH11-TEF1pI/M-ctXDH-CVC1E-EN02pI/L)-ppXKS-ADH2t This study pXF3X23 pR5116-PDC1pI/M-csXR-ADH11-TEF1pI/M-ctXDH-CVC1E-EN02pI/L)-ppXKS-ADH2t This study pXF3X24 pR5116-PDC1pI/M-csXR-ADH11-TEF1pI/M-ctXDH-CVC1E-EN02pI/M-ppXKS-ADH2t	pXF3X09	pRS416-PDC1p(L)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2	This study		
pXF3X11 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(L)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X13 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(L)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X13 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(M)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X15 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(M)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X16 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(M)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X16 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(M)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X17 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(M)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X18 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(M)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X21 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(M)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X23 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(M)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X24 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(M)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X25 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(M)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study pXF3X24 pR5416+PDC1p(M)-csXR-ADH11-TEF1p(M)-ctXDH-CYC1E-EN02p(M)-ppXKS-ADH2t This study	pXF3X10	pRS416-PDC1p(M)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO	This study		
pXF3X12 pR5416-PDC1p(M)-csXR-ADH1tTEF1p(U)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X13 pR5416-PDC1p(M)-csXR-ADH1tTEF1p(M)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X14 pR5416-PDC1p(M)-csXR-ADH1tTEF1p(M)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X15 pR5416-PDC1p(M)-csXR-ADH1tTEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X16 pR5416-PDC1p(M)-csXR-ADH1tTEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X18 pR5416-PDC1p(M)-csXR-ADH1tTEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X19 pR5416-PDC1p(H)-csXR-ADH1tTEF1p(L)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X21 pR5416-PDC1p(H)-csXR-ADH1tTEF1p(L)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X21 pR5416-PDC1p(H)-csXR-ADH1tTEF1p(L)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X23 pR5416-PDC1p(H)-csXR-ADH1tTEF1p(L)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X24 pR5416-PDC1p(H)-csXR-ADH1tTEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X25 pR5416-PDC1p(H)-csXR-ADH1tTEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X25 pR5416-PDC1p(H)-csXR-ADH1tTEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study	pXF3X11	pRS416-PDC1p(M)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t			
pK3X13 pR5416-PDC1p(M)-cxRA-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pKF3X16 pR5416-PDC1p(M)-cxRA-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pKF3X16 pR5416-PDC1p(M)-cxRA-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pKF3X16 pR5416-PDC1p(M)-cxRA-ADH1+TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pKF3X17 pR5416-PDC1p(M)-cxRA-ADH1+TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pXF3X18 pR5416-PDC1p(H)-cxRA-ADH1+TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pXF3X20 pR5416-PDC1p(H)-cxRA-ADH1+TEF1p(U)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pXF3X21 pR5416-PDC1p(H)-cxRA-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pXF3X22 pR5416-PDC1p(H)-cxRA-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pXF3X24 pR5416-PDC1p(H)-cxRA-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pXF3X25 pR5416-PDC1p(H)-cxRA-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pXF3X26 pR5416-PDC1p(H)-cxRA-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study pXF3X26 pR5416-PDC1p(H)-cxRA-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-pxXKS-ADH2t This study	pXF3X12	pRS416-PDC1p(M)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO	This study		
pK3X14 pK5416-PDC1p(M)-csXR-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pK73X15 pR5416-PDC1p(M)-csXR-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pK73X16 pR5416-PDC1p(M)-csXR-ADH1+TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pK73X17 pR5416-PDC1p(M)-csXR-ADH1+TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pK73X19 pR5416-PDC1p(H)-csXR-ADH1+TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X10 pR5416-PDC1p(H)-csXR-ADH1+TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X20 pR5416-PDC1p(H)-csXR-ADH1+TEF1p(L)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X21 pR5416-PDC1p(H)-csXR-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X23 pR5416-PDC1p(H)-csXR-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X24 pR5416-PDC1p(H)-csXR-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X25 pR5416-PDC1p(H)-csXR-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X24 pR5416-PDC1p(H)-csXR-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X27 pR5416-PDC1p(H)-csXR-ADH1+TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study	pXF3X13	pRS416-PDC1p(M)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENC)2p(L)-ppXKS-ADH2t	This study	
pXF3X15 pR5416-PDC1p(M)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2t This study pXF3X15 pR5416-PDC1p(M)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2t This study pXF3X18 pR5416-PDC1p(M)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2t This study pXF3X18 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2t This study pXF3X19 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t This study pXF3X20 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t This study pXF3X21 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t This study pXF3X23 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t This study pXF3X25 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t This study pXF3X25 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t This study pXF3X26 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t This study pXF3X27 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t This study pXF3X27 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t This study	pXF3X14	pRS416-PDC1p(M)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENC)2p(M)-ppXKS-ADH2t	This study	
pXF3X16 pR5416-PDC1p(M)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X17 pR5416-PDC1p(M)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X19 pR5416-PDC1p(M)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X19 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X21 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X23 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X23 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X24 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X25 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X26 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X27 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X27 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study pXF3X27 pR5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This study	pXF3X15	pRS416-PDC1p(M)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENC)2p(H)-ppXKS-ADH2t	This study	
pXF3X17 pK9416-PDC1p(M)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(M)-ppXKS-ADH2t This study pXF3X18 pK9416-PDC1p(M)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-EN02p(M)-ppXKS-ADH2t This study pXF3X19 pK9416-PDC1p(M)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-EN02p(M)-ppXKS-ADH2t This study pXF3X20 pK9416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-EN02p(M)-ppXKS-ADH2t This study pXF3X21 pK9416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-EN02p(M)-ppXKS-ADH2t This study pXF3X22 pK9416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X24 pK9416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X25 pK9416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X27 pK9416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X27 pK9416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X28 pK9416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X27 pK9416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X8 pK9416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study	pXF3X16	pRS416-PDC1p(M)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENC	2p(L)-ppXKS-ADH2t	This study	
pXF3X18 pK5416-PDC1p(M)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X19 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-EN02p(U)-ppXKS-ADH2t This study pXF3X21 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X22 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X23 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X24 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X25 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X26 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X27 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X27 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X8 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X9 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study pXF3X9 pK5416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-EN02p(H)-ppXKS-ADH2t This study	pXF3X17	pRS416-PDC1p(M)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENC	2p(M)-ppXKS-ADH2t	This study	
pXF3X19pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3X20pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3X21pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3X22pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X23pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X26pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X26pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis stu	pXF3X18	pRS416-PDC1p(M)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENC	2p(H)-ppXKS-ADH2t	This study	
pXF3X20pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3X21pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3X22pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X24pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X25pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X26pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t[40]TXF3XPpRS416-PDC1p(-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t[40]Strains used in this studypS416-PDC1p(-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t[40]KF3XPSame as XF3pXF3XPThis studyXF3XPSame as XF3pXF3XPThis studyXF3XD1Same as XF3pXF3XO3This studyXF3X02Same as XF3pXF3X03This studyXF3X03Same as XF3p	pXF3X19	pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO	2p(L)-ppXKS-ADH2t	This study	
pXF3X21pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3X22pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X23pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3X25pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X26pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p*ppXKS-ADH2tThis studypXF3XPipRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p*ppXKS-ADH2tThis studypXF3XPipRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p*ppXKS-ADH2tThis studypXF3XPipRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p*ppXKS-ADH2tThis studypXF3XPipRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p*ppXKS-ADH2tThis studypXF3XPipS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p*ppXKS-ADH2tThis studypXF3XPipS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p*ppXKS-ADH2tThis studypXF3XPipS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p*ppXKS-ADH2tThis studypXF3XPiSame as XF3pXF3XPiThis studypXF3XPiSame as XF3pXF3XP	pXF3X20	pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t		This study	
pXF3X22 pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-pXKS-ADH2t This study pXF3X23 pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-pXKS-ADH2t This study pXF3X24 pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-pXKS-ADH2t This study pXF3X25 pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-pXKS-ADH2t This study pXF3X26 pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-pXKS-ADH2t This study pXF3X26 pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-pXKS-ADH2t This study pXF3X27 pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-pXKS-ADH2t This study pXF3XP pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p+pXKS-ADH2t This study pXF3XP pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p+pXKS-ADH2t [40] Name Genotype PMaxis Reference Strains used in this study pS416-PDC1 [56] This study XF33 BY4742 MATa his3A1 leu2AD lys2AD ura3AD This study XF34 BY4742 APPD2; pTaFAR_ACC1, pYIACL [36] This study XF33X0 Same as XF3 pXF3X01 Th	pXF3X21	pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(L)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t		This study	
pKF3X23pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3X24pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-pXKS-ADH2tThis studypXF3X25pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(L)-pXKS-ADH2tThis studypXF3X26pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1presKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1presKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p-ppXKS-ADH2tThis studypXF3XP1pRS416-PDC1presKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p-ppXKS-ADH2tThis studypXF3XP1pRS416-PDC1presKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p-ppXKS-ADH2tThis studypXF3XP1pRS416-PDC1presKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p-ppXKS-ADH2tThis studypXF3XP1pRS416-PDC1presKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p-ppXKS-ADH2tThis studypXF3XP1pRS416-PDC1presKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2presKR-ADH2tpXF3XP1pK132D1resKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2presKR-ADH2tpXF3XP1pK132D1resKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2presKR-ADH2tpXF3XP1pK132D1resKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2presKR-ADH2tpXF3XP1pXF3XD1resKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2presKR-ADH2tpXF3XP1pXF3XD1resKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2presKR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2pp	pXF3X22	pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2t		This study	
pXF3X24pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3X25pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p(-sxR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p-ppXKS-ADH2tThis studypXF3XPipRS416-PDC1p(-sxR-ADH1t-TEF1p-ctXDH-CYC1t-ENO2p-ppXKS-ADH2tThis studypXF3XPipRS416-PDC1p*-csXR-ADH1t-TEF1p*PRS416-PDC1p*pXF3XPipRS416-PDC1p*ReferenceStrains used in this studyBY4742 ΔRPD3: pTaFAR_ACC1, pYIACL[36]XF33BY4742 ΔRPD3: pTaFAR_ACC1, pYIACL[36]XF3XPSame as XF3pXF3XPiThis studyXF3X01Same as XF3pXF3X01This studyXF3X02Same as XF3pXF3X04This studyXF3X04Same as XF3pXF3X04This studyXF3X05Same as XF3pXF3X06This studyXF3X06Same as XF3pXF3X06This studyXF3X08Same as XF3pXF3X06This studyXF3X09Same as XF3pXF3X06This studyXF3X08Same as XF3pXF3X07This studyXF3X08Same as XF3pXF3X08This studyXF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X08This studyXF3X08Same as XF3pXF3X08 </td <td>pXF3X23</td> <td colspan="2">pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t</td> <td>This study</td> <td></td>	pXF3X23	pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t		This study	
pXF3X25pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(L)-ppXKS-ADH2tThis studypXF3X26pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p*-csXR-ADH1t-TEF1p*-ctXDH-CYC1t-ENO2p*-ppXKS-ADH2t(40)NameGenotypePlasmidsReferenceStrains used in this study(36)Strains used in this studySame as XF3pXF3XPThis studySY4742MATa his3A1 leu2A0 lys2A0 ura3A0(36)XF3XPSame as XF3pXF3XPThis studyYF3X01Same as XF3pXF3XPThis studyXF3X03Same as XF3pXF3X01This studyXF3X04Same as XF3pXF3X03This studyXF3X05Same as XF3pXF3X04This studyXF3X06Same as XF3pXF3X05This studyXF3X07Same as XF3pXF3X06This studyXF3X08Same as XF3pXF3X07This studyXF3X09Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X09Same as XF3pXF3X08This studyXF3X07Same as XF3pXF3X07This studyXF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X09Same as XF3	pXF3X24	pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(M)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t		This study	
pXF3X26pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2tThis studypXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p*csXR-ADH1t-TEF1p-ctXDH-CYC1t-ENO2p*ppXKS-ADH2tThis studypXF3XPipRS416-PDC1p*csXR-ADH1t-TEF1p*ctXDH-CYC1t-ENO2p*ppXKS-ADH2t[40]NameGenotypePlasmidsReferenceStrains used in this studyStrains used in this study<	pXF3X25	pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO	This study		
pXF3X27pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2tThis studypXF3XPpRS416-PDC1p-csXR-ADH1t-TEF1p-ctXDH-CYC1t-ENO2p-ppXKS-ADH2tThis studypXF3XP1pRS416-PDC1p*-csXR-ADH1t-TEF1p*-ctXDH-CYC1t-ENO2p*-ppXKS-ADH2t[40]NameGenotypePlasmidsReferenceStrains used in this studyFY4742MATa his3a1 leu2dolys2do ura3do[36]XF3BY4742 LARPD3: pTaFAR_ACC1, pYIACL[36]XF3XPSame as XF3pXF3XP1This studyXF3X01Same as XF3pXF3X01This studyXF3X03Same as XF3pXF3X03This studyXF3X04Same as XF3pXF3X03This studyXF3X05Same as XF3pXF3X06This studyXF3X06Same as XF3pXF3X06This studyXF3X06Same as XF3pXF3X07This studyXF3X08Same as XF3pXF3X07This studyXF3X09Same as XF3pXF3X07This studyXF3X09Same as XF3pXF3X09This studyXF3X09Same as XF3pXF3X09This studyXF3X00Same as XF3pXF3X09This studyXF3X09Same as XF3pXF3X09This studyXF3X09Same as XF3pXF3X09This studyXF3X00Same as XF3pXF3X09This studyXF3X01Same as XF3pXF3X09This studyXF3X09Same as XF3pXF3X09This studyXF3X09Same as XF3pXF3X09This studyXF3X	pXF3X26	pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(M)-ppXKS-ADH2t This sti			
pXF3XPpRS416-PDC1p-csXR-ADH1t-TEF1p-ctXDH-CYC1t-ENO2p-ppXKS-ADH2tThis studypXF3XPipRS416-PDC1p*csXR-ADH1t-TEF1p*ctXDH-CYC1t-ENO2p*ppXKS-ADH2t[40]NameGenotypePlasmidsReferenceStrains used in this studyMATa his3A1 leu2A0 lys2A0 ura3A0[36]XF3XPBY4742 ARPD3: pTaFAR_ACC1, pYIACL[36]XF3XPSame as XF3pXF3XPThis studyXF3X01Same as XF3pXF3XPiThis studyXF3X02Same as XF3pXF3X01This studyXF3X03Same as XF3pXF3X03This studyXF3X04Same as XF3pXF3X04This studyXF3X05Same as XF3pXF3X04This studyXF3X06Same as XF3pXF3X05This studyXF3X06Same as XF3pXF3X06This studyXF3X07Same as XF3pXF3X06This studyXF3X08Same as XF3pXF3X07This studyXF3X09Same as XF3pXF3X07This studyXF3X09Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X07This studyXF3X09Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X09Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X00Same as XF3pXF3X08This	pXF3X27	pRS416-PDC1p(H)-csXR-ADH1t-TEF1p(H)-ctXDH-CYC1t-ENO2p(H)-ppXKS-ADH2t This study		This study	
pXF3XPipRS416-PDC1p*-csXR-ADH1t-TEF1p*-ctXDH-CYC1t-ENO2p*-ppXKS-ADH2t[40]NameGenotypePlasmidsReferenceStrains used in this studyBY4742MATa his3A1 leu2A0 lys2A0 ura3A0[36]XF33BY4742 ΔRPD3: pTaFAR_ACC1, pYIACL[36]XF3XPSame as XF3pXF3XPSame as XF3pXF3XPiThis studyXF3X01Same as XF3XF3X02Same as XF3SATS3pXF3X01XF3X03Same as XF3XF3X04Same as XF3XF3X05Same as XF3XF3X06Same as XF3XF3X07Same as XF3XF3X08Same as XF3XF3X09Same as XF3XF3X10Same as XF3XF3X10Same as XF3XF3X11This study	pXF3XP	pRS416-PDC1p-csXR-ADH1t-TEF1p-ctXDH-CYC1t-ENO2p-ppXKS-ADH2t This study			
NameGenotypePlasmidsReferenceStrains used in this studyBY4742MATa his3∆1 leu2∆0 lys2∆0 ura3∆0XF3BY4742 △RPD3: pTaFAR_ACC1, pYIACL.XF3BY4742 △RPD3: pTaFAR_ACC1, pYIACL.XF3XPSame as XF3XF3XPSame as XF3XF3X01Same as XF3XF3X02Same as XF3XF3X03Same as XF3XF3X04Same as XF3XF3X05Same as XF3XF3X06Same as XF3XF3X07Same as XF3XF3X08Same as XF3XF3X09Same as XF3XF3X10Same as XF3XF3X11This studyXF3X11This study	pXF3XPi	pRS416-PDC1p*-csXR-ADH1t-TEF1p*-ctXDH-CYC1t-ENO2p*-ppXKS-ADH2t [40]		[40]	
Strains used in this studyBY4742MATa his3∆1 leu2∆0 lys2∆0 ura3∆0XF3BY4742 ∆RPD3: pTaFAR_ACC1, pYIACL[36]XF3XPSame as XF3pXF3XPXF3XPISame as XF3pXF3XPiXF3X01Same as XF3pXF3X01XF3X02Same as XF3pXF3X02XF3X03Same as XF3pXF3X02XF3X04Same as XF3pXF3X04XF3X05Same as XF3pXF3X04XF3X06Same as XF3pXF3X05XF3X07Same as XF3pXF3X06XF3X08Same as XF3pXF3X07XF3X08Same as XF3pXF3X08XF3X09Same as XF3pXF3X09XF3X09Same as XF3pXF3X09XF3X09Same as XF3pXF3X09XF3X09Same as XF3pXF3X09XF3X09Same as XF3pXF3X09XF3X10Same as XF3pXF3X10XF3X11Same as XF3pXF3X11XF3X11Same as XF3pXF3X11	Name	Genotype	Plasmids		Reference
BY4742MATa his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0XF3BY4742 ΔRPD3: pTaFAR_ACC1, pYIACL[36]XF3XPSame as XF3pXF3XPThis studyXF3XPiSame as XF3pXF3XPiThis studyXF3X01Same as XF3pXF3X01This studyXF3X02Same as XF3pXF3X02This studyXF3X03Same as XF3pXF3X03This studyXF3X04Same as XF3pXF3X04This studyXF3X05Same as XF3pXF3X05This studyXF3X06Same as XF3pXF3X06This studyXF3X07Same as XF3pXF3X08This studyXF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X09This studyXF3X11Same as XF3pXF3X11This study	Strains used in this study				
XF3BY4742 ΔRPD3: pTaFAR_ACC1, pYIACL[36]XF3XPSame as XF3pXF3XPThis studyXF3XPiSame as XF3pXF3XPiThis studyXF3X01Same as XF3pXF3X01This studyXF3X02Same as XF3pXF3X02This studyXF3X03Same as XF3pXF3X03This studyXF3X04Same as XF3pXF3X04This studyXF3X05Same as XF3pXF3X05This studyXF3X06Same as XF3pXF3X06This studyXF3X07Same as XF3pXF3X07This studyXF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X01This studyXF3X11Same as XF3pXF3X11This study	BY4742	MATa his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0			
XF3XPSame as XF3pXF3XPThis studyXF3XPiSame as XF3pXF3XPiThis studyXF3X01Same as XF3pXF3X01This studyXF3X02Same as XF3pXF3X02This studyXF3X03Same as XF3pXF3X03This studyXF3X04Same as XF3pXF3X04This studyXF3X05Same as XF3pXF3X05This studyXF3X06Same as XF3pXF3X06This studyXF3X07Same as XF3pXF3X06This studyXF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3	BY4742 Δ <i>RPD3</i> : pTaFAR_ACC1, pYIACL			[36]
XF3XPiSame as XF3pXF3XPiThis studyXF3X01Same as XF3pXF3X01This studyXF3X02Same as XF3pXF3X02This studyXF3X03Same as XF3pXF3X03This studyXF3X04Same as XF3pXF3X04This studyXF3X05Same as XF3pXF3X05This studyXF3X06Same as XF3pXF3X06This studyXF3X07Same as XF3pXF3X06This studyXF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3XP	Same as XF3	pXF3XP		This study
XF3X01Same as XF3pXF3X01This studyXF3X02Same as XF3pXF3X02This studyXF3X03Same as XF3pXF3X03This studyXF3X04Same as XF3pXF3X04This studyXF3X05Same as XF3pXF3X05This studyXF3X06Same as XF3pXF3X06This studyXF3X07Same as XF3pXF3X06This studyXF3X08Same as XF3pXF3X07This studyXF3X09Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3XPi	Same as XF3	pXF3XPi		This study
XF3X02Same as XF3pXF3X02This studyXF3X03Same as XF3pXF3X03This studyXF3X04Same as XF3pXF3X04This studyXF3X05Same as XF3pXF3X05This studyXF3X06Same as XF3pXF3X06This studyXF3X07Same as XF3pXF3X07This studyXF3X08Same as XF3pXF3X07This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3X01	Same as XF3 pXF3X01			This study
XF3X03Same as XF3pXF3X03This studyXF3X04Same as XF3pXF3X04This studyXF3X05Same as XF3pXF3X05This studyXF3X06Same as XF3pXF3X06This studyXF3X07Same as XF3pXF3X07This studyXF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3X02	Same as XF3 DXF3X02			This study
XF3X04Same as XF3pXF3X04This studyXF3X05Same as XF3pXF3X05This studyXF3X06Same as XF3pXF3X06This studyXF3X07Same as XF3pXF3X07This studyXF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3X03	Same as XF3 pXF3X03			This study
XF3X05Same as XF3pXF3X05This studyXF3X06Same as XF3pXF3X06This studyXF3X07Same as XF3pXF3X07This studyXF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3X04	Same as XF3 pXF3X04			This study
XF3X06Same as XF3pXF3X06This studyXF3X07Same as XF3pXF3X07This studyXF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3X05	Same as XF3 pXF3X05			This study
XF3X07Same as XF3pXF3X07This studyXF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3X06	Same as XF3	pXF3X06		This study
XF3X08Same as XF3pXF3X08This studyXF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3X07	Same as XF3 pXF3X07			This study
XF3X09Same as XF3pXF3X09This studyXF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3X08	Same as XF3 pXF3X08			This study
XF3X10Same as XF3pXF3X10This studyXF3X11Same as XF3pXF3X11This study	XF3X09	Same as XF3 pXF3X09			This study
XF3X11Same as XF3pXF3X11This study	XF3X10	Same as XF3	pXF3X10		This study
	XF3X11	Same as XF3	pXF3X11		This study

Reference

Name	Genotype	Plasmids	Reference
XF3X12	Same as XF3	pXF3X12	This study
XF3X13	Same as XF3	pXF3X13	This study
XF3X14	Same as XF3	pXF3X14	This study
XF3X15	Same as XF3	pXF3X15	This study
XF3X16	Same as XF3	pXF3X16	This study
XF3X17	Same as XF3	pXF3X17	This study
XF3X18	Same as XF3	pXF3X18	This study
XF3X19	Same as XF3	pXF3X19	This study
XF3X20	Same as XF3	pXF3X20	This study
XF3X21	Same as XF3	pXF3X21	This study
XF3X22	Same as XF3	pXF3X22	This study
XF3X23	Same as XF3	pXF3X23	This study
XF3X24	Same as XF3	pXF3X24	This study
XF3X25	Same as XF3	pXF3X25	This study
XF3X26	Same as XF3	pXF3X26	This study
XF3X27	Same as XF3	pXF3X27	This study

Table 1 continued

* Mutated promoters used for ethanol production [40]

with forward primer (XF FP csXR ADH1t) and reverse primer (XF_RP_csXR_ADH1t); the ctXDH was amplified with forward primer (XF_FP_ TEF1p _CYC1t) and reverse primer (XF_RP_ctXDH_CYC1t); the ppXKS was amplified with forward primer (XF_FP_ppXKS_ADH2t) and reverse primer (XF_FP_ppXKS_ADH2t). The resulting PCR fragments have a 40 bp region homologous to constitutive yeast promoters and terminators, respectively. The constitutive yeast PDC1p promoters with different strengths for csXR were amplified with forward primer (XF_FP_PDC1p) and reverse primer (XF_RP_ PDC1p) and using mutant PDC1p templates [28]. The different versions of TEF1p promoters for ctXDH and ENO2p promoters for ppXKS were achieved using the same methods. The DNA Assembler method was next used to construct the xylose utilization plasmids pRS416-PDC1p (L/M/H)-csXR-ADH1t-TEF1p(L/M/H)-ctXDH-CYC1t-ENO2p(L/M/H)-ppXKS-ADH2t with the proper combinations of each fragment (Fig. 1b). The sequences of all mutated promoters were listed in Additional file 1: Table S2.

Determination of 1-hexadecanol production

The 1-hexadecanol was detected using a method previously described [3]. In general, for screening the 1-hexadecanol production in different strains, the engineered yeast strains were pre-cultured in 3 mL SC medium including all the appropriate nucleotides and amino acids, with 2 % glucose for 3 days until saturation. The cells were then centrifuged and washed twice with double-distilled water. The cell pellets were next inoculated into 5 mL fresh SC medium with 40 g/L xylose in disposable glass tubes overlaid with 10 % dodecane to prevent the evaporation of fatty alcohols and enrich the fatty alcohol in the organic layer to ease the measurement [3]. The concentrations of 1-hexadecanol were quantified at 48 h [3]. The glass tubes of yeast cultures were allowed to sit for 2 min until the organic layer could be clearly visualized. Then, 3 µL of dodecane was withdrawn from the organic layer and diluted by 100 times using ethyl acetate and analyzed by GC-MS (ShimadzuGC-MS-QP2010) with a DB-Wax column with 0.25 µm film thickness, 0.25 mm diameter, and 30 m length (Agilent Inc., Palo Alto, CA). Tridecane at a concentration of 2 mg/L was used as the internal standard. The GC program was as follows: an initial temperature of 50 °C was maintained for 1.5 min, followed by ramping to 180 °C at a rate of 25 °C/min. The temperature was then ramped to 250 °C at a rate of 10 °C/min, where the temperature was held for 3 min.

Evolutionary engineering

To improve xylose utilization of the engineered strain, the optimized strain was cultured and serial-transferred into 50 mL of fresh SC medium with 40 g/L xylose as the sole carbon source in a closed 100 mL flask. The cells were grown until the early stationary phase (~3 days) and spread on SC-xylose plates. After 3-days growth, the biggest colony was inoculated into a fresh medium and grown until the early stationary phase. Then the cells were sub-cultured with 5 % inoculums in biological triplicates into fresh medium for the second round



evolutionary engineering using the SC medium with 40 g/L xylose. The cells were grown for 3 days with typical OD_{600} in the range of 1.5–2.5. For each round of cell culture, the cell growth rate and fatty alcohol titer were measured using the method described above. We

checked the plasmids intactness for each generation of the evolved strains by colony PCR, amplifying the cassettes for each gene, and confirming the intactness by DNA electrophoresis. All the plasmids were found to be intact (Additional file 1: Figure S1).

Batch and fed-batch fermentation

Both XF3XP and XF3XP07 yeast strains were first grown in 100 mL SC medium including all the appropriate nucleotides and amino acids, with 20 g/L glucose for 2 days. Then, cells from 5 mL of culture were centrifuged, washed twice with double-distilled water, and inoculated into 5 mL fresh SC medium with 40 g/L xylose in glass disposable tubes overlaid with 0.5 mL dodecane for batch fermentation. The initial ODs were similar, i.e., 2.38 \pm 0.05 and 2.45 \pm 0.06, with no significant difference (p > 0.05). Samples were taken at various time points to measure the 1-hexadecanol concentration, OD_{600} , and xylose concentration. At each time point, the glass tubes of yeast cultures were allowed to sit for 2 min until the organic layer could be clearly visualized. To measure the 1-hexadecanol concentration, 3 µL of dodecane was withdrawn from the organic layer and then diluted by 100 times using ethyl acetate followed by the analysis using the GC-MS protocol mentioned above. To monitor OD_{600} , 20 µL of yeast culture was taken from the water layer and mixed with 180 µL of doubledistilled water, followed by measuring the absorbance at 600 nm using a Biotek Synergy 2 Multi-Mode Microplate Reader (Winooski, VT). To measure the concentration of xylose, 100 μ L of yeast culture was taken from the water layer and mixed with 900 µL of double-distilled water, which was then centrifuged at 13,000 rpm for 5 min. The supernatant was taken and analyzed by Shimadzu HPLC (Columbia, MD) equipped with an Aminex HPX-87H column (Bio-Rad, Hercules, CA) and Shimadzu RID-10A refractive index detector. The column was kept at 50 °C, and 5 mM sulfuric acid solution was used as a mobile phase with a constant flow rate of 0.6 mL/min. Each data point represents the mean of triplicate samples. In this discontinuous fed-batch fermentation, additional xylose (0.5 mL with concentration of 200 g/L) and dodecane (0.05 mL) were fed every 12 h. Samples were taken after the replenishment to measure 1-hexadecanol concentration, OD_{600} , and xylose concentration using the similar methods as that for batch fermentation. The biological triplicates were implemented in both batch and fed-batch fermentation for all the strains.

Results and discussion

Constructing a xylose utilization pathway in a fatty alcohol-producing strain

In order to produce the xylose-based 1-hexadecanol, we first introduced the fungal xylose utilization pathway [29] into a 1-hexadecanol-producing *S. cerevisiae* strain, XF3 [10] (Fig. 1). The xylose utilization pathway was selected from our previous study [29], which included a XR from *Candida shehatae*, a XDH from *Candida tropicalis* and a XKS from *Pichia pastoris*. The XF3 strain produced

1-hexadecanol at over 1.1 g/L from glucose in S. cerevisiae as reported in our previous study [10]. The 1-hexadecanol production in XF3 was achieved by heterologously expressing a FAR from barn owls, over-expressing acetyl-CoA carboxylase (ACC1 gene), knocking out a negative regulator, RPD3 gene, in phospholipid synthesis, and over-expressing ATP-citrate lyases (ACL1 gene and ACL2 gene) from Yarrowia lipolytica to enhancing the supply of cytosolic acetyl-CoA (Fig. 1a). By introducing the fungal xylose utilization pathway into XF3 strain, we successfully generated a S. cerevisiae strain (XF3XP) to produce the 1-hexadecanol from xylose as the sole carbon source at 0.4 g/L (Table 2). The xylose-based fatty alcohol titer was lower than the glucose-based 1-hexadecanol titer [10] and only 15 g/L xylose was consumed to produce 1-hexadecanol, indicating the xylose utilization could be a rate-limiting step for fatty alcohol production. We also introduced another fungal xylose pathway in which the promoter strengths of XR, XDH, and XKS were previously optimized to increase xylose-based ethanol production (XF3XPi, Table 2). We found that although 1-hexadecanol production could be increased to 0.48 g/L, the xylose utilization was even worse than the wild-type pathway with less than 5 g/L xylose consumed. This is possibly due to the fact that the regulatory mechanism adopted by S. cerevisiae to control xylosebased fatty alcohol production was different from that to control xylose-based ethanol production. Therefore, the metabolic engineering of S. cerevisiae for biofuel production is target-specific.

Promoter engineering to improve 1-hexadecanol production from xylose

In order to further improve the 1-hexadecanol production, we implemented a synthetic biology approach called Customized Optimization of Metabolic Pathways by Combinatorial Transcriptional Engineering (COM-PACTER) [28] to precisely control the gene expression levels of XR, XDH, and XKS. Basically, we chose three constitutive promoters, P_{PDC1} , P_{TEF1} , and P_{ENO2} to express XR, XDH and XKS genes, respectively. For each of the constitutive promoters, we mutated the

Table 2 Batch fermentation profiles of engineered *S. cerevisiae* strains

Strains	Xylose con- sumed (g/L)	Growth rate (h ⁻¹)	1-hexadecanol (g/L)	Ethanol (g/L)
XF3XP	14.9 ± 0.3	0.093 ± 0.009	0.40 ± 0.10	1.41 ± 0.32
XF3XPi	4.5 ± 0.4	0.096 ± 0.010	0.48 ± 0.09	0.48 ± 0.07
XF3XP07	7.8 ± 1.3	0.073 ± 0.007	0.79 ± 0.10	0.00 ± 0.00

original promoters to create a promoter library with varving strengths. We then selected promoters with high, medium, and low strengths (Additional file 1: Figure S2) for P_{PDC1}, P_{TEF1}, and P_{ENO2}, respectively, and constructed totally 27 synthetic xylose pathways $(3 \times 3 \times 3 = 27)$ in S. cerevisiae with all of the promoter combinations of P_{PDC1} , P_{TEF1} , and P_{ENO2} with different strengths (Fig. 1b; Table 1). We next compared the growth rates and 1-hexadecanol titers of all the recombinant S. cerevisiae strains to that of the control strains, XF3XP (Fig. 2). It is worth noticing that the purpose of combinatorial promoter screening was to find the strain with the highest fatty alcohol production from xylose instead of the best xylose utilization strain. Therefore, we did not measure the xylose utilization rates here. We found that the growth rates of most of the promoter-engineered strains were reduced to some extent, and the 1-hexadecanol production for most of the recombinant strains was not significantly improved. However, strain XF3X07 and XF3X25 produced 1-hexadecanol at 171 and 140 % higher than that of the control strains with a slightly deceased growth rates $(0.073 h^{-1} and 0.080 h^{-1})$ compared with the growth rate of the control strain (0.093 h^{-1}). Both XF3X07 and

XF3X25 used a high-level TEF1 promoter to express XDH and a low-level ENO2 promoter to express XKS. Nevertheless, XF3X07 used a low-level PDC1 promoter to express XR while XF3X25 used a high-level PDC1 promoter. This discovery is consistent with previous studies showing that the XDH enzymes were rate-limiting steps in converting xylose to biomass and ethanol [30, 31]. Interestingly, despite of higher titer of 1-hexadecanol in XF3X07 compared to XF3XPi, the xylose-based 1-hexadecanol yields were similar in XF3XP07 and XF3XPi (p > 0.1). This indicated that the combinatorial promoter engineering mainly improved the xylose uptake rate instead of optimizing the host pathways to improve the conversion of xylose to 1-hexadecanol.

We correlated the strengths of promoters for XR, XDH, and XKS with the two measured parameters, 1-hexadecanol concentrations and growth rates (Additional file 1: Figure S3). No correlation was observed between promoter strengths and 1-hexadecanol concentrations. Neither did we find the correlation between promoter strengths and growth rates. We also correlated 1-hexadecanol concentrations and growth rates, but found no correlation between them either (Additional file 1: Figure



S4). Therefore, it is unfeasible to solely use the results of promoter screening to make predictions on the choice of promoters that should be used for xylose-based production of 1-hexadecanol. This is because the introduction of xylose pathways would trigger the global metabolic rewiring, as we found previously when investigating metabolic responses to different xylose utilization pathways via ¹³C metabolic flux analysis [32]. This global metabolic rewiring involves the reprogramming of not only xylose pathway itself but also the downstream pathways, which made the xylose metabolism too complex to be correlated with the activity of xylose utilization pathway itself.

Evolutionary engineering to improve 1-hexadecanol production from xylose

We next chose XF3X07 and XF3X25 as our target strains for further evolutionary engineering to improve the 1-hexadecanol production. Evolutionary engineering has been widely used to improve the pentose utilization and xylose-based ethanol production in S. cerevisiae successfully [33–35]. Considering the poor xylose uptake in our engineered strains, we implemented the evolutionary engineering to investigate whether fatty alcohol production is growth-associated, and if so, to further improve the xylose-based fatty alcohol production. Similar as the study of combinatorial promoter screening, our goal of evolutionary engineering is to seek a yeast strain that could produce fatty alcohols from xylose as much as possible. Therefore, we did not measure the xylose utilization rates. In general, we serially transfer the strain XF3X07 and XF3X25 to synthetic medium with 40 g/L xylose twice. Namely, the optimized strain was the second generation evolved from the wild-type strain. We found that the growth rates of two strains increased gradually (~25 and ~ 35 %) for every round as expected. However, such increase was associated with reduced 1-hexadecanol production. For example, the highest growth rate was reached for both XF3X07 and XF3X25 with the lowest titer of 1-hexadecanol in the second round (Fig. 3). The growth rates of the evolved strains in the last round were significantly increased for XF3XP07 and XF3XP25 (p < 0.05). However, the 1-hexadecanol productions were not significantly changed (p > 0.05). Such discrepancy indicated that 1-hexadecanol, unlike ethanol, was not a growth-associated product. Since evolutionary engineering selects the mutant strain with higher growth rate, the 1-hexadecanol production failed to be further improved via adaptive evolution due to the de-coupling between the cell growth rate and the fatty alcohol production. In addition, we applied flux balance analysis to calculate the ATP, NADH, and NADPH synthesis under different 1-hexadecanol productions (Additional file 1: Figure S5). We found that the NADPH and ATP synthesis were positively correlated with 1-hexadecanol production, while NADH synthesis did not change too much with the 1-hexadecanol synthesis. Overall, the evolutionary engineering approach would be helpful to improve the cell growth and growth-associated products such as ethanol, but not for non-growth associated products such as fatty acid-derived chemicals.

Batch and fed-batch fermentation for 1-hexadecanol production

With XF3XP07 as our best strain to produce xylose-based 1-hexadecanol, we next characterized its 1-hexadecanol production using batch and fed-batch fermentation. In batch fermentation, we found that 0.79 g/L 1-hexadecanol was produced from 7.8 g/L xylose, with a cell growth rate at 0.073 h⁻¹ (Table 2). This 1-hexadecanol titer of XF3XP07 is significantly higher than the ones of



XF3XP and XF3XPi strain (p < 0.05). More interestingly, comparing the xylose uptakes of the XF3XP and XF3XPi, we found the XF3XP strain consumed three-fold more xylose than the XF3XPi strain. This additional xylose was mainly used to produce more ethanol in XF3XP strains (Table 2). In addition, we have measured the accumulation of intracellular 1-hexadecanol, which was less than 5 % of the extracellular concentration of 1-hexadecanol from the organic layer. Such low accumulation is consistent with several previous studies when yeast was cultured with an organic layer [36], although it is also reported that *S. cerevisiae* strains could accumulate a large amount of fatty alcohols intracellularly when cultured without the organic layer [37].

In fed-batch fermentation, we used resting cells for fermentation, i.e., the cell density was kept at high level to prevent using the xylose to produce biomass. Although the fermentation at high cell density might limit the oxygen supply for the fermentation, which is an important factor for the optimal expression of the xylose pathway genes [38], the marginal net growth rate of yeast cells could be more important in fed-batch fermentation because it was found in this study that fatty alcohol production was not growth-associated and hence by removing the biomass production, yeast cells could serve as biocatalysts to convert xylose to 1-hexadecanol with high efficiency. We found that a long lag phase lasting around 40 h in the fed-batch fermentation, which could be due to the repression of residue glucose from the inoculum since we cultured XF3XP and XF3XP07 with 20 g/L glucose before transferring the cells into the medium with xylose, and hence cells needed a long time to accustom to xylose from glucose (Fig. 4). For the XF3XP strain, 1-hexadecanol has been produced quickly with a low xylose consumption, and achieved ~0.6 g/L of 1-hexadecanol at 48 h (Fig. 4a). For the XP3XP07 strain, after the long lag phase, 1-hexadecanol was produced rapidly with the increased xylose uptake and reached the highest titer of 1-hexadecanol at 1.2 g/L at the 69 h (Fig. 4b). However, when continuing the fed-batch fermentation for both strains, both the 1-hexadecanol concentrations and xylose uptake rates were decreased. The observed low xylose consumption rate accompanied with the decrease of OD_{600} suggested a starvation because of the incapability to further uptake the carbon substrate and the probable limitation by other nutrients such as nitrogen and phosphate after the 50 h of the fermentation. In our previous study [10], we found that fatty alcohols could be taken up by *S. cerevisiae*, which could be the reason for the decreased fatty alcohol production when xylose utilization became limited.

Comparing the xylose-based fatty alcohol production to the glucose-based one in the previous study, the similar titer of fatty alcohol from fed-batch fermentation has been observed, demonstrating the successful integration of xylose utilization pathway and the fatty alcohol production pathway. However, the yields of xylose-based fatty alcohols in both batch (0.10 \pm 0.02 g/g) and fedbatch fermentation (0.08 \pm 0.01 g/g) were much higher than that of glucose-based ones (~0.03 and <0.01 g/g), respectively. The theoretical maximum yields through this production pathway from xylose and glucose were ~0.34 and ~0.35 (g/g), respectively. In this case, the yield from xylose reached nearly one-third of the theoretical yield, while the yield from glucose only reached less than 10 % of the theoretical yield. The bypass of ethanol production when feeding xylose instead of glucose likely attributed to the high yield of xylose-based 1-hexadecanol, which could divert more carbons to be utilized in the fatty alcohol production rather than ethanol production.



Conclusion

A fatty alcohol-producing S. cerevisiae strain was engineered in this study to produce 1-hexadecanol from xylose. To achieve this, a xylose utilization pathway consisting of XR, XDH and XK was heterologously expressed in S. cerevisiae, followed by optimization of the xylose-based fatty alcohol production through promoter engineering and evolutionary engineering to improve 1-hexadecanol production by 171 %. Through fed-batch fermentation, the highest titer of 1-hexadecanol reached 1.2 g/L with xylose used as the sole carbon source. Although the xylose pathway we developed in this study was still not optimal, this proof-of-concept study, for the first time to our best knowledge, indicated that the xylose-based fatty alcohol could be achieved in S. cerevisiae with potential applications in developing consolidated bioprocessing for producing fatty acid-derived chemicals.

Additional file

Additional file 1: Table S1. Primers used in this study. Table S2. Promoters used in this study. Figure S1. DNA electrophoresis confirmed that all of the cassettes in both xylose pathway and 1-hexadecanol pathway existed in the evolved strains. Figure S2. The strengths of PDC1, TEF1, and ENO2 promoters in front of EGFP. Figure S3. Correlations between the promoter strengths in front of XR, XDH and XKS in xylose utilization pathways and the growth rates (blue dots) as well as 1-hexadecanol concentrations (red dots). Figure S4. Correlation between the growth rates and the 1-hexadecanol titers for the combinatorial promoter engineering. Figure S5. Flux balance analysis revealed correlation between the 1-hexadecanol production and ATP (A), NADH (B), NADPH (C), and growth rate (D)

Abbreviations

ACC: acetyl-CoA carboxylase; ACL: ATP-citrate lyase; AcCoA: acetyl-CoA; ACR: acyl-CoA reductase; AR: aldehyde reductases; CAR: carboxylic acid reductase; CIT: citrate; E4P: erythrose 4-phosphate; F6P: fructose 6-phosphate; FAS: fatty-acyl-CoA synthase; FBP: fructose 1,6-bisphosphate; G6P: glucose 6-phosphate; GAP: glyceraldehyde 3-phosphate; INO1: inositol-3-phosphate synthase; MAL: malate; OAA: oxaloacetate; PYR: pyruvate; R5P: ribose 5-phosphate; Ru5P: ribulose 5-phosphate; S7P: sedoheptulose 7-phosphate; TCA cycle: tricarbo-xylic acid cycle; X5P: xylulose 5-phosphate; XR: xylose reductase; XDH: xylitol dehydrogenase; XKS: xylulose kinase.

Authors' contributions

XF carried out the promoter engineering experiments. JS and XF carried out the molecular genetic studies, participated in the evolutionary experiments. WG and JS carried out the batch and fed-batch fermentation experiments. WG carried out the computation analysis and data processing. WG and JS drafted the manuscript. XF and HZ conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Author details

¹ Department of Biological Systems Engineering, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA.² Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

Acknowledgements

We thank the writing center in Virginia Tech for improving the language of the paper. This study was supported by start-up fund (#175323) from Virginia Tech (X.F.) and Energy Biosciences Institute (OO7G21) (H.Z.).

Competing interests

The authors declare that they have no competing interests.

Received: 16 September 2015 Accepted: 19 January 2016 Published online: 01 February 2016

References

- 1. Liu R, Zhu F, Lu L, Fu A, Lu J, Deng Z, Liu T. Metabolic engineering of fatty acyl-ACP reductase-dependent pathway to improve fatty alcohol production in *Escherichia coli*. Metab Eng. 2014;22:10–21.
- Du J, Shao Z, Zhao H. Engineering microbial factories for synthesis of value-added products. J Ind Microbiol Biotechnol. 2011;38(8):873–90.
- Runguphan W, Keasling JD. Metabolic engineering of Saccharomyces cerevisiae for production of fatty acid-derived biofuels and chemicals. Metab Eng. 2014;21:103–13.
- Youngquist JT, Schumacher MH, Rose JP, Raines TC, Politz MC, Copeland MF, Pfleger BF. Production of medium chain length fatty alcohols from glucose in *Escherichia coli*. Metab Eng. 2013;20:177–86.
- Mudge SM, Belanger SE, Nielsen AM. Fatty alcohols: anthropogenic and natural occurrence in the environment. Cambridge: The Royal Society of Chemistry; 2008.
- Rupilius W, Ahmad S. Palm oil and palm kernel oil as raw materials for basic oleochemicals and biodiesel. Eur J Lipid Sci Technol. 2007;109(4):433–9.
- Fitzherbert E, Struebig M, Morel A, Danielsen F, Brühl C, Donald P, Phalan B. How will oil palm expansion affect biodiversity? Trends Ecol Evol. 2008;23(10):538–45.
- Hill J, Nelson E, Tilman D, Polasky S, Tiffany D. Environmental, economic, and energetic costs and benefits of biodiesel and ethanol biofuels. Proc Natl Acad Sci USA. 2006;103(30):11206–10.
- Zhang F, Rodriguez S, Keasling JD. Metabolic engineering of microbial pathways for advanced biofuels production. Curr Opin Biotechnol. 2011;22(6):775–83.
- 10. Feng X, Lian J, Zhao H. Metabolic engineering of *Saccharomyces cerevisiae* to improve 1-hexadecanol production. Metab Eng. 2015;27:10–9.
- Cao YX, Xiao WH, Liu D, Zhang JL, Ding MZ, Yuan YJ. Biosynthesis of oddchain fatty alcohols in *Escherichia coli*. Metab Eng. 2015;29:113–23.
- Fillet S, Gibert J, Suárez B, Lara A, Ronchel C, Adrio J. Fatty alcohols production by oleaginous yeast. J Ind Microbiol Biotechnol. 2015;42(11):1463–72.
- Zheng Y, Li L, Liu Q, Yang J, Wang X, Liu W, Xu X, Liu H, Zhao G, Xian M. Optimization of fatty alcohol biosynthesis pathway for selectively enhanced production of C12/14 and C16/18 fatty alcohols in engineered *Escherichia coli*. Microb Cell Fact. 2012;11:65.
- Akhtar MK, Turner NJ, Jones PR. Carboxylic acid reductase is a versatile enzyme for the conversion of fatty acids into fuels and chemical commodities. Proc Natl Acad Sci USA. 2013;110(1):87–92.
- Liu A, Tan X, Yao L, Lu X. Fatty alcohol production in engineered *E. coli* expressing Marinobacter fatty acyl-CoA reductases. Appl Microbiol Biotechnol. 2013;97(15):7061–71.
- Hong KK, Nielsen J. Metabolic engineering of Saccharomyces cerevisiae: a key cell factory platform for future biorefineries. Cell Mol Life Sci. 2012;69(16):2671–90.
- Wei N, Quarterman J, Kim SR, Cate JH, Jin YS. Enhanced biofuel production through coupled acetic acid and xylose consumption by engineered yeast. Nature Commun. 2013;4:2580.
- Jeffries T, Jin Y. Metabolic engineering for improved fermentation of pentoses by yeasts. Appl Microbiol Biotechnol. 2004;63(5):495–509.
- Eliasson A, Christensson C, Wahlbom CF, Hahn-Hagerdal B. Anaerobic xylose fermentation by recombinant *Saccharomyces cerevisiae* carrying XYL1, XYL2, and XKS1 in mineral medium chemostat cultures. Appl Environ Microbiol. 2000;66(8):3381–6.

- 20. Kim B, Du J, Eriksen DT, Zhao H. Combinatorial design of a highly efficient xylose-utilizing pathway in *Saccharomyces cerevisiae* for the production of cellulosic biofuels. Appl Environ Microbiol. 2013;79(3):931–41.
- Garcia Sanchez R, Karhumaa K, Fonseca C, Sanchez Nogue V, Almeida JR, Larsson CU, Bengtsson O, Bettiga M, Hahn-Hagerdal B, Gorwa-Grauslund MF. Improved xylose and arabinose utilization by an industrial recombinant *Saccharomyces cerevisiae* strain using evolutionary engineering. Biotechnol Biofuels. 2010;3(1):1–11.
- Kuyper M, Harhangi HR, Stave AK, Winkler AA, Jetten MS, de Laat WT, den Ridder JJ, OpdenCamp HJ, van Dijken JP, Pronk JT. High-level functional expression of a fungal xylose isomerase: the key to efficient ethanolic fermentation of xylose by *Saccharomyces cerevisiae*? FEMS Yeast Res. 2003;4(1):69–78.
- Zhou H, Cheng J-S, Wang B, Fink GR, Stephanopoulos G. Xylose isomerase overexpression along with engineering of the pentose phosphate pathway and evolutionary engineering enable rapid xylose utilization and ethanol production by *Saccharomyces cerevisiae*. Metab Eng. 2012;14(6):611–22.
- 24. Demeke MM, Dietz H, Li Y, Foulquié-Moreno MR, Mutturi S, Deprez S, Den Abt T, Bonini BM, Liden G, Dumortier F, et al. Development of a D-xylose fermenting and inhibitor tolerant industrial *Saccharomyces cerevisiae* strain with high performance in lignocellulose hydrolysates using metabolic and evolutionary engineering. Biotechnol Biofuels. 2013;6(1):1–24.
- Gietz R, Schiestl R. High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc. 2007;2(1):31–4.
- Shao Z, Zhao H, Zhao H. DNA assembler, an in vivo genetic method for rapid construction of biochemical pathways. Nucleic Acids Res. 2009;27(2):e16.
- Shao Z, Luo Y, Zhao H. Rapid characterization and engineering of natural product biosynthetic pathways via DNA assembler. Mol BioSyst. 2011;7(4):1056–9.
- Du J, Yuan Y, Si T, Lian J, Zhao H. Customized optimization of metabolic pathways by combinatorial transcriptional engineering. Nucleic Acids Res. 2012;40(18):e142.

- 29. Feng X, Zhao H. Investigating host dependence of xylose utilization in recombinant *Saccharomyces cerevisiae* strains using RNA-seq analysis. Biotechnol Biofuels. 2013;6:95.
- 30. Young E, Lee S, Alper H. Optimizing pentose utilization in yeast: the need for novel tools and approaches. Biotechnol Biofuels. 2010;3:24.
- Toivari MH, Salusjärvi L, Ruohonen L, Penttilä M. Endogenous Xylose Pathway in *Saccharomyces cerevisiae*. Appl Environ Microbiol. 2004;70(6):3681–6.
- 32. Feng X, Zhao H. Investigating xylose metabolism in recombinant *Saccharomyces cerevisiae* via 13C metabolic flux analysis. Microb Cell Fact. 2013;12(1):114.
- Kuyper M, Toirkens MJ, Diderich JA, Winkler AA, van Dijken JP, Pronk JT. Evolutionary engineering of mixed-sugar utilization by a xylose-fermenting Saccharomyces cerevisiae strain. FEMS Yeast Res. 2005;5(10):925–34.
- Scalcinati G, Otero JM, Van Vleet JR, Jeffries TW, Olsson L, Nielsen J. Evolutionary engineering of *Saccharomyces cerevisiae* for efficient aerobic xylose consumption. FEMS Yeast Res. 2012;12(5):582–97.
- Sonderegger M, Sauer U. Evolutionary engineering of Saccharomyces cerevisiae for anaerobic growth on xylose. Appl Environ Microbiol. 2003;69(4):1990–8.
- 36. Feng X, Lian J, Zhao H. Metabolic engineering of *Saccharomyces cerevisiae* to improve 1-hexadecanol production. Metab Eng. 2015;27:10–9.
- Tang X, Chen WN. Enhanced production of fatty alcohols by engineering the TAGs synthesis pathway in *Saccharomyces cerevisiae*. Biotechnol Bioeng. 2015;112(2):386–92.
- Latimer LN, Lee ME, Medina-Cleghorn D, Kohnz RA, Nomura DK, Dueber JE. Employing a combinatorial expression approach to characterize xylose utilization in *Saccharomyces cerevisiae*. Metab Eng. 2014;25:20–9.
- Lian J, Si T, Nair NU, Zhao H. Design and construction of acetyl-CoA overproducing Saccharomyces cerevisiae strains. Metab Eng. 2014;24:139–49.
- Du J, Yuan Y, Si T, Lian J, Zhao H. Customized optimization of metabolic pathways by combinatorial transcriptional engineering. Nucleic Acids Res. 2012;40(18):e142.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit

